Open clinical trial on the sigma ligand panamesine in patients with schizophrenia

  title={Open clinical trial on the sigma ligand panamesine in patients with schizophrenia},
  author={R M Frieboes and Harald Murck and Klaus Wiedemann and Florian Holsboer and Axel Steiger},
The sigma (σ) receptor has been proposed as a target of neuroleptic drugs. Preclinical data suggest that panamesine (EMD 57445), a novel σ ligand, has antipsychotic effects and is free of side effects related to the extrapyramidal motoric system (EPMS). Here we report the results of an exploratory study aimed at determining the appropriate dose range and the safety of panamesine in patients with an acute episode of schizophrenia. The first trial with four patients revealed insufficient clinical… CONTINUE READING
13 Citations
40 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 13 extracted citations


Publications referenced by this paper.
Showing 1-10 of 40 references

EMD 57445: a selective sigma receptor ligand with the proÞle of an atypical neuroleptic

  • GD Bartoszyk, HM Bender, J Hellmann, C Schnorr, CA Seyfried
  • CNS Drug Rev 2:175–194
  • 1996
Highly Influential
5 Excerpts

The extrapyramidal symptom rating scale

  • G Chouinard, A Ross-Chouinard, L Annable, BD Jones
  • Can J Neurol Sci
  • 1980
Highly Influential
4 Excerpts

A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. US Department of Health, Education

  • A Rechtscha¤en, A Kales
  • 1968
Highly Influential
3 Excerpts

Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress

  • HY Meltzer
  • 1995
1 Excerpt

Similar Papers

Loading similar papers…